Biotechnology The European Investment Bank (EIB) has signed two financing deals under the Investment Plan with companies developing treatments for cancer. The first is 15 million ($16.7 million) for Italian biotech company MolMed, which will use the financing for research and clinical trials for gene and cell therapies as treatments for cancer and rare diseases. 18 December 2019